AMEX · Biotechnology

Can-Fite BioPharma Ltd. (CANF) Stock

$3.30 -2.37% AMEX: CANF Healthcare

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction.

Valuation

MetricValue
Price$3.30
Market Cap$1.78M
P/E Ratio-0.74
P/B Ratio0.66
P/S Ratio21634.62
EPS (TTM)$-12.03
52-Week High$21.00
52-Week Low$2.56
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-201.06%
ROA-103.30%
ROCE-146.69%
Gross Margin100.00%
Operating Margin—
Net Margin—
Debt/Equity0.01
Current Ratio3.46

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$1.0M$1.0M$0
Operating Profit$-13.0M$-10.0M$-8.0M$-8.0M$-10.0M
Net Profit$-13.0M$-10.0M$-8.0M$-8.0M$-10.0M
EPS$-8.25$-3.75$-1.80$-1.08$-12.03
Op Margin-1505.5%-1246.4%-1103.0%-1206.2%-2456.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$20.0M$9.0M$10.0M$9.0M$10.0M
Total Liabilities$6.0M$5.0M$4.0M$4.0M$4.0M
Cash$4.0M$3.0M$4.0M$5.0M$6.0M
Borrowings$0$0$0$0$0

Latest News

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer GlobeNewswire · Jul 14, 2026 Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 GlobeNewswire · Jul 6, 2026 Sector Update: Healthcare Stocks Higher Late Afternoon MT Newswires · Jul 1, 2026 Sector Update: Healthcare Stocks Advance in Afternoon Trading MT Newswires · Jul 1, 2026 Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease GlobeNewswire · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-10.0M$-11.0M$-8.0M$-8.0M$-9.0M
Investing Cash Flow$-15.0M$9.0M$0$1.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$-4.0M$-1.0M$1.0M$1.0M$1.0M
Free Cash Flow$-10.0M$-11.0M$-8.0M$-8.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-882.18
FCF Yield-0.10%
Quick Ratio3.46
Interest Coverage0.00
Return 1Y-83.82%
Return 3Y-94.50%
Return 5Y-99.23%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BDRXBiodexa Pharmaceuticals Plc $1.71 -3.39% 0.00 $1.28M 0.00%
CLDI $0.11 +0.18% -0.03 $802266 0.00%
CMND $1.62 +0.52% -0.79 $2.41M 0.00%
CNSP $5.40 +0.75% -0.14 $3.10M 0.00%
GRI $1.46 -5.81% -0.33 $131155 0.00%

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.

Can-Fite BioPharma Ltd. is headquartered in IL.

Can-Fite BioPharma Ltd. (CANF) stock trades at $3.30 with a market capitalization of $1.78M. The stock is valued at a price-to-earnings (P/E) ratio of -0.74, price-to-book of 0.66, price-to-sales of 21634.62. Over the past 52 weeks the stock has ranged between $2.56 and $21.00, and currently trades 84.3% below its 52-week high.

On profitability, Can-Fite BioPharma Ltd. generates a return on equity (ROE) of -201.06%, return on capital employed of -146.69%.

Official website: www.canfite.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides